gRNA Market Report Scope & Overview:

Get more information on gRNA Market - Request Free Sample Report

The gRNA Market Size was valued at USD 498.30 Million in 2023, and is expected to reach USD 2,303.70 Million by 2032, and grow at a CAGR of 19.61% Over the Forecast Period of 2024-2032.

A rise in genomic investment and increasing adoption of gene-editing technologies are the key factors promoting the development of the gRNA market. According to the most recent statistics provided by the NIH, federal investment in genomic research has increased significantly. In 2023, the NIH is planning to invest USD 2.3 billion in genomic studies which makes up a 15% increase from the data of the previous year. The growing number of research activities and development of new gene editing tools, including gRNA vital for the CRISPR-related processes, stimulates further market promotion.

Additionally, the increased risk of genetic diseases and the need for personalized medication and other interventions also increase the interest in the field. As for the overall number of research, the number of active research projects increased by as much as 20% over the last year, which means about 250 new projects adopted the technology over this time. Finally, technological development is also accelerating the growth of the market by increasing the number of CRISPR applications with a particular focus on therapeutics.

gRNA Market Dynamics:

Key Drivers:

• The Widespread Adoption of CRISPR-Cas9 for Gene Editing has Significantly Boosted the Demand for gRNA

• Governments and Private Entities are Heavily Investing in Genomic Research and Biotechnology, Driving the Growth of the gRNA Market

Restraints:

• Ethical Concerns and Stringent Regulatory Frameworks Surrounding Gene Editing Technologies Pose Significant Challenges to The Expansion of the gRNA Market

• The Development and Implementation of gRNA-Based Technologies are Cost-Intensive Limiting the Market Growth

Opportunity:

• The Application of gRNA in Agricultural Biotechnology for Crop Improvement and Pest Resistance Presents Substantial Growth Opportunities.

• The growing Focus on Biotechnology and Life Sciences Research in Emerging Markets Like Asia-Pacific and Latin America Provides New Avenues For gRNA Market Expansion

gRNA Market Segment Analysis:

By Type

In 2023, the research-use segment dominated the market share, accounting for 65%. A large number of research programs are being conducted across various research institutes, and as a result, a highly filed the use of research-grade gRNA. Moreover, there is an increasing application of gRNA in the clinical research sector, which is further driving the demand for the same. Thus, the segment is expected to continue its dominance over the forecast period. The highest CAGR is estimated for the GMP-grade segment. The segment is required for the production of smooth and quality gRNA under quality control and regulatory guidelines for performing clinical trials and usage of samples in the patients. GMP focuses on enforcing procedures that assure high levels of quality assurance. The emphasis is put on appropriate design, monitoring, and control of manufacturing processes and facilities. The availability of such products and the importance of such products in the medical sector is expected to drive the market. The gene editing market is expected to be driven by the availability of GMP-grade gRNA, making it popular for use in personalized medicine. In addition to this, due to the use of GMP in the process of production, there is no chance of contamination or adulteration, leading to increased shelf life of the product. Subsequently, making it more affordable for the end-user.

Get Customized Report as per your Business Requirement - Request For Customized Report

By Application

The genome engineering segment dominated the global market share in 2023 with 45% and has been anticipated to grow at the fastest CAGR during the forecast period Genome engineering is highly lucrative for the application of gRNA, as the field of genome engineering is creating massive changes in disparate multitude of industry. The precision and the versatile nature of gRNA within the CRISPR-based editing methods have revolutionized the prospects of genetic modifications. The highest positive impact is seen in the fields of medicine, agriculture, and biotechnology. Synthetic biology depends on genome engineering with gRNA for the design and construction of new synthetic biological parts, organisms, devices, and systems for useful purposes. Industrial biotechnology will use this information to engineer microbial strains for the optimization of the production of biofuels, and drugs, and further increase the demand for genome engineering and hence, drive the market growth.

gRNA Market Regional Oveview:

North America, with a revenue of 53% contributed to the largest share of the overall global market in 2023. The increasing gRNA industry growth is due to the presence of a substantial number of key players in the local markets, for instance, Thermo Fisher Scientific, Inc.; and Merck KGaA.; among others. Besides, the gRNA market is growing due to a spike in the research and development spending of the key market players to develop their products to be innovative and advanced. For instance, in May 2023, Thermo Fisher Scientific, Inc. and Pfizer, Inc. entered a collaboration to expand access to NGS-based testing for cancer patients. Both companies will focus on lung and breast cancer, two of the most common and deadly cancers worldwide. Following the partnership, there is expected to be an increasing demand for gRNAs that target the genes related to cancer. During the forecast timeframe, the CAGR of the Asia Pacific region is predicted to be the highest. The probability of growth is due to the presence of a substantial population who can be the target patients. In addition, this is guaranteed by the fact that in Asia Pacific, the adoption of a broad range of technologies is quicker, and there are a great number of startups as well. Growing healthcare infrastructure and the local high-unmet clinical needs will be of help to key manufacturers.

KEY PLAYERS:

The key market players are Jena Bioscience GmbH, Thermo Fisher Scientific Inc., Synbio Technologies, Merck KGaA, Takara Bio Inc., Horizon Discovery Ltd., Agilent Technologies Inc., System Biosciences, LLC., Synthego, GENEWIZ (Azenta Life Sciences) & other players.

RECENT DEVELOPMENTS

• In May 2023, Revvity Inc. acquired Horizon Discovery Ltd., a life sciences and diagnostic business of PerkinElmer, Inc.

• In May 2023, a rebranding of the PerkinElmer life sciences and diagnostics arm was announced, calling it Revvity.

• In July 2022, Synthego opened the 20,000-square-foot manufacturing facility aimed at delivering GMP single guide RNA at scale. In October 2021, Merck KGaA agreed to license its CRISPR-Cas9 technology to Cellecta, Inc., a functional genomics products and services provider based in the U.S.